Lukasz Szafron
Overview
Explore the profile of Lukasz Szafron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szostakowska-Rodzos M, Fabisiewicz A, Wakula M, Tabor S, Szafron L, Jagiello-Gruszfeld A, et al.
Sci Rep
. 2024 Jun;
14(1):12924.
PMID: 38839863
Hormone-responsive breast cancer represents the most common type and has the best prognosis, but still approximately 40% of patients with this type can develop distant metastases, dramatically worsening the patient's...
2.
Trebinska-Stryjewska A, Szafron L, Rembiszewska A, Wakula M, Tabor S, Sienkiewicz R, et al.
J Oncol
. 2019 May;
2019:6375025.
PMID: 31093284
HAX1 is an antiapoptotic factor involved in the regulation of cell migration and calcium homeostasis, overexpressed in several cancers, including breast cancer. It has been suggested that HAX1 is also...
3.
Sromek M, Glogowski M, Chechlinska M, Kulinczak M, Szafron L, Zakrzewska K, et al.
Cell Oncol (Dordr)
. 2017 Jun;
40(5):529-536.
PMID: 28634901
Purpose: The majority of non-small cell lung cancer (NSCLC) patients presents with an advanced-stage disease and, consequently, exhibits a poor overall survival rate. We aimed to assess changes in plasma...
4.
Phelan C, Kuchenbaecker K, Tyrer J, Kar S, Lawrenson K, Winham S, et al.
Nat Genet
. 2017 Mar;
49(5):680-691.
PMID: 28346442
To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified...
5.
Ong J, Cuellar-Partida G, Lu Y, Fasching P, Hein A, Burghaus S, et al.
Int J Epidemiol
. 2016 Sep;
45(5):1619-1630.
PMID: 27594614
Background: In vitro and observational epidemiological studies suggest that vitamin D may play a role in cancer prevention. However, the relationship between vitamin D and ovarian cancer is uncertain, with...
6.
Cuellar-Partida G, Lu Y, Dixon S, Fasching P, Hein A, Burghaus S, et al.
Hum Genet
. 2016 Apr;
135(7):741-56.
PMID: 27075448
Epithelial ovarian cancer (EOC) is one of the deadliest common cancers. The five most common types of disease are high-grade and low-grade serous, endometrioid, mucinous and clear cell carcinoma. Each...
7.
Lu Y, Cuellar-Partida G, Painter J, Nyholt D, Morris A, Fasching P, et al.
Hum Mol Genet
. 2015 Aug;
24(20):5955-64.
PMID: 26231222
Epidemiological studies have demonstrated associations between endometriosis and certain histotypes of ovarian cancer, including clear cell, low-grade serous and endometrioid carcinomas. We aimed to determine whether the observed associations might...
8.
Moes-Sosnowska J, Szafron L, Nowakowska D, Dansonka-Mieszkowska A, Budzilowska A, Konopka B, et al.
Orphanet J Rare Dis
. 2015 Apr;
10:32.
PMID: 25886974
Background: SMARCA4 mutations have recently been identified as driving lesions of the ovarian small cell carcinoma of hypercalcemic type (SCCHT). Familial occurrence of this neoplasm was described previously. Methods: We...
9.
Felisiak-Golabek A, Dansonka-Mieszkowska A, Rzepecka I, Szafron L, Kwiatkowska E, Konopka B, et al.
Cancer Biol Ther
. 2013 Sep;
14(10):973-81.
PMID: 24022213
p19(INK4d) (CDKN2D) is a negative regulator of the cell cycle. Little is known of its role in cancer development and prognosis. We aimed to evaluate the clinical significance of p19(INK4d)...
10.
Rzepecka I, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, et al.
Cancer Genet
. 2012 Apr;
205(3):94-100.
PMID: 22469508
BRCA1 dysfunction may occur by different mechanisms that are rarely evaluated concomitantly. We aimed to analyze BRCA1 germline mutations, loss of heterozygosity (LOH) and promoter methylation in unselected ovarian carcinomas...